PASIREOTIDE DIASPARTATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2012)
Entry Type: Protein
Molecule Category: Salt
UNII: I4P76SY3N4
Parent Compound: PASIREOTIDE

Structure
InChI Key NEEFMPSSNFRRNC-PPCPDXGKSA-N
Smile NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O.N[C@@H](CC(=O)O)C(=O)O.N[C@@H](CC(=O)O)C(=O)O
InChI
InChI=1S/C58H66N10O9.2C4H7NO4/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45;2*5-2(4(8)9)1-3(6)7/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72);2*2H,1,5H2,(H,6,7)(H,8,9)/t43-,46-,47-,48+,49-,50-,51-;2*2-/m000/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C66H80N12O17
Molecular Weight 1313.43
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Pharmacology

Action Mechanism of Action Reference
AGONIST Somatostatin receptor 1 agonist

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Hypoglycemia 2 D007003 ClinicalTrials

Related Entries

Scaffolds

Parent

Side Effects from Label

Side effects Relative Frequency (%) Labels
Endocrine disorders Pituitary-dependent Cushing's syndrome 83.3
Gastrointestinal disorders Diarrhoea 58.5
Gastrointestinal disorders Diarrhoea 58.0
Gastrointestinal disorders Diarrhoea 57.5
Gastrointestinal disorders Nausea 57.5
Gastrointestinal disorders Nausea 51.9
Gastrointestinal disorders Nausea 46.3
Endocrine disorders Hyperglycaemia 42.5
Endocrine disorders Hyperglycaemia 40.1
Endocrine disorders Hyperglycaemia 37.8
Hepatobiliary disorders Cholelithiasis 30.5
Hepatobiliary disorders Cholelithiasis 30.2
Hepatobiliary disorders Cholelithiasis 30.0
Nervous system disorders Headache 28.7
Nervous system disorders Headache 28.4
Nervous system disorders Headache 28.0
Gastrointestinal disorders Abdominal pain 25.0
Gastrointestinal disorders Gastrointestinal pain 25.0
Gastrointestinal disorders Abdominal pain 24.1
Gastrointestinal disorders Gastrointestinal pain 24.1
General disorders and administration site conditions Asthenia 23.8
General disorders and administration site conditions Fatigue 23.8
Gastrointestinal disorders Abdominal pain 23.2
Gastrointestinal disorders Gastrointestinal pain 23.2
Endocrine disorders Diabetes mellitus 20.0
General disorders and administration site conditions Asthenia 19.1
General disorders and administration site conditions Fatigue 19.1
Endocrine disorders Diabetes mellitus 17.9
General disorders and administration site conditions Injection site reaction 17.5
General disorders and administration site conditions Injection site reaction 17.3
General disorders and administration site conditions Injection site reaction 17.1
General disorders and administration site conditions Asthenia 15.9
Endocrine disorders Diabetes mellitus 15.9
General disorders and administration site conditions Asthenia 14.6
General disorders and administration site conditions Fatigue 14.6
Endocrine disorders Hypoglycaemia 14.6
Nervous system disorders Insomnia 13.8
Infections and infestations Nasopharyngitis 13.8
Investigations Alanine aminotransferase increased 13.4
Infections and infestations Nasopharyngitis 13.0
Skin and subcutaneous tissue disorders Alopecia 12.5
Skin and subcutaneous tissue disorders Alopecia 12.3
Gastrointestinal disorders Abdominal pain upper 12.2
Skin and subcutaneous tissue disorders Alopecia 12.2
Investigations Gamma-glutamyltransferase increased 12.2
Investigations Glycosylated haemoglobin increased 12.2
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 12.2
Musculoskeletal and connective tissue disorders Myalgia 12.2
Infections and infestations Nasopharyngitis 12.2
Endocrine disorders Type 2 diabetes mellitus 12.2
Psychiatric disorders Anxiety 11.2
General disorders and administration site conditions Decreased appetite 11.2
Metabolism and nutrition disorders Hypercholesterolaemia 11.2
General disorders and administration site conditions Asthenia 11.1
Investigations Glycosylated haemoglobin increased 11.1
Infections and infestations Influenza 11.0
Cardiac disorders Oedema peripheral 11.0
Investigations Alanine aminotransferase increased 10.5
Investigations Gamma-glutamyltransferase increased 10.5
Cardiac disorders Oedema peripheral 10.5
Musculoskeletal and connective tissue disorders Arthralgia 10.0
Investigations Glycosylated haemoglobin increased 10.0
Vascular disorders Hypertension 10.0
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 10.0
Cardiac disorders Oedema peripheral 10.0
Gastrointestinal disorders Vomiting 10.0
Gastrointestinal disorders Abdominal pain upper 9.88
General disorders and administration site conditions Decreased appetite 9.88
Metabolism and nutrition disorders Hypercholesterolaemia 9.88
Vascular disorders Hypertension 9.88
Cardiac disorders Dizziness 9.76
Vascular disorders Hypertension 9.76
Cardiac disorders Sinus bradycardia 9.76
Cardiac disorders Dizziness 9.26
Endocrine disorders Hypoglycaemia 9.26
Endocrine disorders Type 2 diabetes mellitus 9.26
Cardiac disorders Dizziness 8.75
Investigations Gamma-glutamyltransferase increased 8.75
Skin and subcutaneous tissue disorders Pruritus 8.75
Psychiatric disorders Anxiety 8.64
Infections and infestations Influenza 8.64
Nervous system disorders Insomnia 8.64
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 8.64
Musculoskeletal and connective tissue disorders Myalgia 8.64
Gastrointestinal disorders Constipation 8.54
General disorders and administration site conditions Decreased appetite 8.54
Metabolism and nutrition disorders Hypercholesterolaemia 8.54
Investigations Lipase increased 8.54
Musculoskeletal and connective tissue disorders Arthralgia 8.02
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 8.02
Skin and subcutaneous tissue disorders Pruritus 8.02
Gastrointestinal disorders Abdominal pain upper 7.5
Investigations Alanine aminotransferase increased 7.5
Musculoskeletal and connective tissue disorders Back pain 7.5
Vascular disorders Hypotension 7.5
Ear and labyrinth disorders Vertigo 7.5
Investigations Lipase increased 7.41
Investigations Aspartate aminotransferase increased 7.32
Investigations Blood glucose increased 7.32
Metabolism and nutrition disorders Hypokalaemia 7.32
Musculoskeletal and connective tissue disorders Pain in extremity 7.32
Skin and subcutaneous tissue disorders Pruritus 7.32
Gastrointestinal disorders Constipation 6.79
Vascular disorders Hypotension 6.79
Gastrointestinal disorders Vomiting 6.79
Gastrointestinal disorders Abdominal distension 6.25
Endocrine disorders Adrenal insufficiency 6.25
General disorders and administration site conditions Asthenia 6.25
Skin and subcutaneous tissue disorders Dry skin 6.25
Investigations Electrocardiogram QT prolonged 6.25
Infections and infestations Influenza 6.25
Investigations Lipase increased 6.25
Endocrine disorders Type 2 diabetes mellitus 6.25
Musculoskeletal and connective tissue disorders Back pain 6.17
Skin and subcutaneous tissue disorders Dry skin 6.17
Investigations Electrocardiogram QT prolonged 6.17
Metabolism and nutrition disorders Hypokalaemia 6.17
Musculoskeletal and connective tissue disorders Pain in extremity 6.17
Cardiac disorders Sinus bradycardia 6.17
Ear and labyrinth disorders Vertigo 6.17
Psychiatric disorders Anxiety 6.1
Musculoskeletal and connective tissue disorders Arthralgia 6.1
Skin and subcutaneous tissue disorders Dry skin 6.1
Investigations Electrocardiogram QT prolonged 6.1
Vascular disorders Hypotension 6.1
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 6.1
Gastrointestinal disorders Abdominal distension 5.56
Endocrine disorders Adrenal insufficiency 5.56
Investigations Aspartate aminotransferase increased 5.56
Investigations Blood glucose increased 5.56
Gastrointestinal disorders Constipation 5.0
Metabolism and nutrition disorders Hypokalaemia 5.0
Musculoskeletal and connective tissue disorders Musculoskeletal discomfort 5.0
Musculoskeletal and connective tissue disorders Myalgia 5.0
Musculoskeletal and connective tissue disorders Pain in extremity 5.0
Gastrointestinal disorders Abdominal distension 4.88
Endocrine disorders Adrenal insufficiency 4.88
Musculoskeletal and connective tissue disorders Back pain 4.88
Ear and labyrinth disorders Vertigo 4.88
Blood and lymphatic system disorders Anaemia 4.0
Investigations Aspartate aminotransferase increased 3.75
Investigations Blood glucose increased 3.75
Endocrine disorders Hypoglycaemia 3.75
Nervous system disorders Insomnia 3.66
Gastrointestinal disorders Vomiting 3.66
Cardiac disorders Sinus bradycardia 2.5
Investigations Amylase increased 2.0
Investigations Prothrombin level increased 2.0

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Metabolism and nutrition disorders
12.65
Endocrine disorders
11.23
Gastrointestinal disorders
10.23
General disorders and administration site conditions
9.96
Investigations
9.47
Nervous system disorders
8.08
Vascular disorders
4.77
Cardiac disorders
4.55
Hepatobiliary disorders
3.9
Musculoskeletal and connective tissue disorders
3.63
Injury, poisoning and procedural complications
3.33
Infections and infestations
3.11
Psychiatric disorders
2.61
Skin and subcutaneous tissue disorders
2.57
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
2.5
Renal and urinary disorders
2.12
Respiratory, thoracic and mediastinal disorders
2.1

Cross References

Resources Reference
ChEMBL CHEMBL3039588
FDA SRS I4P76SY3N4
PubChem 73354270
CONTENTS